Key result
Among elderly Medicare patients with atrial fibrillation, 51.3% were not prescribed an oral anticoagulant, with age ≥ 85 years and intracranial bleeding strongly predicting lower utilization.
Why the study?
Oral anticoagulants reduce stroke risk in atrial fibrillation, but their underutilization patterns require analysis.
What are the prevalence and predictors of oral anticoagulant underutilization in elderly Medicare patients with incident atrial fibrillation and elevated stroke risk?
Cohort (n=1,204,507)
What are the prevalence and predictors of oral anticoagulant underutilization in elderly Medicare patients with incident atrial fibrillation and elevated stroke risk?
Despite guideline recommendations, over half of elderly Medicare patients with incident atrial fibrillation and elevated stroke risk are not prescribed oral anticoagulants, with underutilization strongly predicted by advanced age, female sex, Black race, and bleeding history.
Answers are grounded in this paper and cite their sources.
Persistent OAC underutilization in elderly Medicare AF patients signals care gaps; leaves open targeted interventions pending prospective data.
BACKGROUND: Oral anticoagulants (OACs) mitigate stroke risk in patients with atrial fibrillation (AF). The study aim was to analyze prevalence and predictors of OAC underutilization. Patients were stratified based on having an OAC prescription versus not and the OAC prescription group was stratified by direct OAC (DOACs) versus warfarin. Multivariable logistic regression models were used to examine predictors of OAC underutilization. RESULTS: Among 1,204,507 identified AF patients, 617,611 patients (51.3%) were not prescribed an OAC during follow-up (mean: 2.4 years), and 586,896 patients (48.7%) were prescribed an OAC during this period (DOAC: 388,629 [66.2%]; warfarin: 198,267 [33.8%]). Age ≥ 85 years (odds ratio [OR] 0.55, 95% confidence interval [CI] 0.55-0.56), female sex (OR 0.96, 95% CI 0.95-0.96), Black race (OR 0.78, 95% CI 0.77-0.79) and comorbidities such as gastrointestinal (GI; OR 0.43, 95% CI 0.41-0.44) and intracranial bleeding (OR 0.29, 95% CI 0.28-0.31) were associated with lower utilization of OACs. Furthermore, age ≥ 85 years (OR 0.92, 95% CI 0.91-0.94), Black race (OR 0.78, 95% CI 0.76-0.80), ischemic stroke (OR 0.77, 95% CI 0.75-0.80), GI bleeding (OR 0.73, 95% CI 0.68-0.77), and intracranial bleeding (OR 0.72, 95% CI 0.65-0.80) predicted lower use of DOACs versus warfarin. CONCLUSIONS: Although OAC therapy prescription is the standard of care for stroke prevention in AF patients, its overall utilization is still low among Medicare patients ≥ 65 years old, with specific patient characteristics that predict underutilization.
No takes yet. Share an insight, caveat, or question.
Munir et al. (2022) conducted a cohort in Atrial fibrillation (n=1,204,507). Age ≥ 85 years vs. Younger age groups was evaluated on Oral anticoagulant (OAC) prescription (OR 0.55, 95% CI 0.55-0.56). Among elderly Medicare patients with atrial fibrillation, 51.3% were not prescribed an oral anticoagulant, with age ≥ 85 years and intracranial bleeding strongly predicting lower utilization.
Synapse has enriched 10 related papers. Consider them for comparative context: